Blueprint Medicines Corporation
BPMC · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Market Cap | $6 | $6 | $6 | $7 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $1 |
| Enterprise Value | $6 | $6 | $6 | $8 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 2.1% | 14.2% | -7.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 98.1% | 94.9% | 98.5% | 91.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -27.5% | -18.5% | -26% | -21.3% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 0.3% | -34.1% | -43.9% | -36.2% |
| EPS Diluted | 0.01 | -0.79 | -0.89 | -0.8 |
| % Growth | 101.3% | 11.2% | -11.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |